Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CDC42 | P60953 | 1/20 | 0.51 |
| ▸ | RAC1 | P63000 | 1/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16346363 | 0.86 | KDM4E (0.66) | KDM4ECYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL9196872 | 0.85 | KDM4E (0.64) | KDM4ECYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL9593388 | 0.85 | KDM4E (0.64) | KDM4ECYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL11217337 | 0.83 | KDM4E (0.62) | KDM4ECYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL9592986 | 0.83 | KDM4E (0.62) | KDM4ECYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL30824304 | 0.83 | KDM4E (0.62) | KDM4ECYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL9044944 | 0.83 | KDM4E (0.62) | KDM4ECYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL9046301 | 0.83 | KDM4E (0.62) | KDM4ECYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL9592745 | 0.83 | KDM4E (0.62) | KDM4ECYP1A2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL9529778 | 0.83 | KDM4E (0.62) | KDM4ECYP1A2ALDH1A1HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662844-B2 | Naphthylene derivatives as cytochrome P450 inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1654236-A1 | NAPHTHYLENE DERIVATIVES AS CYTOCHROME P450 INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060009645-A1 | Naphthylene derivatives as cytochrome P450 inhibitors | OSI PHARMACEUTICALS, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005007631-A1 | NAPHTHYLENE DERIVATIVES AS CYTOCHROME P450 INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-4675418-A | Process for preparing alkanoic acids or esters thereof by rearrangement of alpha-halo-ketones in protic medium and in the presence of a non-noble metal salt | BLASCHIM S.P.A. (IT) | 1987-06-23 | — | — | US | disclosed |
| US-4550191-A | Process for preparing esters of 2'-(6'-methoxy-2-naphthyl)-propionic acid | BLASCHIM S.P.A. (IT) | 1985-10-29 | — | — | US | disclosed |
| US-4550191-A | Process for preparing esters of 2'-(6'-methoxy-2-naphthyl)-propionic acid | BLASCHIM S.P.A. (IT) | 1985-10-29 | — | — | US | disclosed |
| EP-0089711-B1 | PROCESS FOR PREPARING ESTERS OF 2-(6'-METHOXY-2'-NAPHTHYL)-PROPIONIC ACID | BLASCHIM S.p.A. (IT) | 1985-09-18 | — | — | EP | disclosed |
| EP-0071299-B1 | PROCESS FOR PREPARING ALKANOIC ACIDS OR ESTERS THEREOF BY REARRANGEMENT OF ALPHA-HALO-KETONES IN PROTIC MEDIUM AND IN THE PRESENCE OF A NON-NOBLE METAL SALT | BLASCHIM S.p.A. (IT) | 1984-10-31 | — | — | EP | disclosed |
| EP-0089711-A2 | Process for preparing esters of 2-(6'-methoxy-2'-naphthyl)-propionic acid | BLASCHIM S.p.A. (IT) | 1983-09-28 | — | — | EP | disclosed |
| EP-0089711-A2 | Process for preparing esters of 2-(6'-methoxy-2'-naphthyl)-propionic acid | BLASCHIM S.p.A. (IT) | 1983-09-28 | — | — | EP | disclosed |
| EP-0071299-A1 | Process for preparing alkanoic acids or esters thereof by rearrangement of alpha-halo-ketones in protic medium and in the presence of a non-noble metal salt | BLASCHIM S.p.A. (IT) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009645-A1 | Naphthylene derivatives as cytochrome P450 inhibitors | CYP1A1, CYP1A2, RARA | KDM4E 4251/4885CYP1A2 2/4885ALDH1A1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.